Although its role has been best studied in breast cancer [14, 16, 18, 19], evidence that JAM-A contributes to glioblastoma, nasopharyngeal, gastric, and lung cancer is also emerging (recently reviewed in [20]). This evidence concerns the gene F11R and breast cancer.